The trial results confirm that the drug is effectively absorbed, is well tolerated, and did not cause any of the side effects observed by other presently available drugs for Alzheimer’s.
Neurodyn completes Part I of Memogain® Phase IA Clinical Trial
This entry was posted in Mertzholdings News. Bookmark the permalink.